Genesco is in the Retail Industry

• Sort by

• Genesco's growth path strewn with brands.

  Genesco Inc. has maintained its strategy of focusing on branded footwear, obtaining just 10% of its shoe business from private label footwear. Footwear is expected to account for 47% of Genesco's net sales in 1994, up from 38% in FY 1993. The Code West anGenesco Inc. has maintained its strategy...

  Research articles 1993-08-09

  Tags: brand, Genesco

• Genesco outlines 5-year growth plan. (Genesco Inc.)

  Newly-appointed CEO E. Douglas Grindstaff of Genesco Inc outlined his company's plans and goals under his leadership in a meeting with shoe industry observers. Genesco, which carries 14 footwear brands, will concentrate on developing strategies for specifNewly-appointed CEO E. Douglas Grindstaff of Genesco Inc outlined his company's plans and goals...

  Research articles 1993-01-25

  Tags: brand, Genesco

• Genesco signs up for University Brands. (acquisition and merger)

  Genesco, a Nashville-based footwear and apparel manufactuer, wholesaler and retailer, plans to expand its presence in the children's footwear market by acquiring University Brands, formerly known as Toddler University, a specialist in the pre-walke Genesco, a Nashville-based footwear and apparel manufactuer, wholesaler and...

  Research articles 1992-12-01

  Tags: acquisition, brand, Genesco, merger

• Genesco agrees to buy Toddler U. (Genesco Inc; University Brands Inc)

  Men's footwear brand Genesco Inc intends to acquire Toddler U Inc after a series of investigations and agreements are completed by the two parties. This move is in line with Genesco's plan of expanding their existing brands and acquiring new ones. The acqMen's footwear brand Genesco Inc intends to acquire...

  Research articles 1992-11-02

  Tags: brand, Genesco

Additional Resources

• MethylGene to Present at Investor Conferences

  MethylGene Inc. (TSX: MYG) today announced that Donald F. Corcoran, President and Chief Executive Officer, will participate in two upcoming investor conferences in New York, one sponsored by Piper Jaffray and the other by RBC Capital Markets. Mr. Corcoran will present at the 20th Annual Piper Jaffray Healthcare Conference on...

  Articles 2008-11-26

• Genesco Reports Third Quarter Fiscal 2009 Sales and Revises Guidance

  NASHVILLE, Tenn., Nov. 18 /PRNewswire-FirstCall/ -- Genesco Inc. today announced that it currently expects to report net sales of approximately $390 million for the third quarter ended November 2, 2008, compared to $372 million for the same period last year, or an increase of 5%. The Company said that...

  Articles 2008-11-18

• MethylGene Reports Third Quarter 2008 Financial Results

  MethylGene Inc. (TSX: MYG), today announced its financial results for the third quarter and nine-month period ended September 30, 2008. Financial Results Reported in Canadian Dollars Revenue for the three-month period ended September 30, 2008 was $5.8 million compared to revenue of $3.7 million for the third quarter of 2007....

  Articles 2008-11-10

• Zacks Releases Four Powerful "Buy" Stocks: ITT Educational Services, Casey's General Stores, Vascular Solutions and Genesco

  CHICAGO -- Four free stock picks are being made available today on Zacks.com. The industry's leading independent research firm highlights one Zacks #1 Rank Strong Buy or a Zacks #2 Rank Buy stock for each of the four main styles of investing: Aggressive Growth, Growth & Income, Momentum, and Value....

  Articles 2008-11-06

• MethylGene Presents Preclinical Data for MGD290, a Hos2 Fungal Inhibitor, at Joint ICAAC/IDSA Annual Meeting

  MethylGene Inc. (TSX: MYG) today disclosed preclinical data for MGCD290, a fungal Hos2 inhibitor to be used in combination with azoles for the treatment of fungal infections. MethylGene is currently evaluating MGCD290 in a Phase I clinical trial. The data were presented in two poster sessions at the joint 48th...

  Articles 2008-10-27

• MethylGene Reacquires Rights to MGCD0103 From Celgene and Implements Strategic Plan to Focus on Development of Proprietary Clinical Pipeline

  MethylGene Inc. (TSX: MYG) today announced that Celgene has terminated their licensing agreement for oncology histone deacetylase HDAC inhibitors, including MGCD0103. As a result, MethylGene will reacquire the rights to these programs. Furthermore, the Company announced that it will implement a strategic initiative to focus its resources on the clinical...

  Articles 2008-10-27

• MethylGene to Present at the 7th Annual BIO Investor Forum

  MethylGene Inc. (TSX: MYG), today announced that Mr. Donald F. Corcoran, President and Chief Executive Officer of MethylGene will present an overview of the Company at the 7th Annual BIO Investor Forum in San Francisco on Thursday, October 30th at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time). About MethylGene...

  Articles 2008-10-23

• MethylGene Presents Preclinical Biomarker Data For MGCD265 at the 20th EORTC-NCI-AACR Symposium

  MethylGene Inc. (TSX: MYG) today disclosed preclinical biomarker data for its kinase inhibitor, MGCD265, in a poster session at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva. MGCD265 is an oral, small molecule, multi-targeted kinase inhibitor that targets c-Met, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor...

  Articles 2008-10-22

• GeneEd Announces Major New Healthcare Education Initiative

  SAN FRANCISCO -- In response to demand from healthcare professionals, clinical scientists, and others, GeneEd, Inc., a leading provider of continuing medical education CME for physicians, nurses, and healthcare workers, is making its disease state database available for licensing to healthcare portals. During the past ten years, GeneEd scientists have...

  Articles 2008-10-20

• MethylGene Initiates Phase I Clinical Study With MGCD290 for Fungal Infections

  MethylGene Inc. (TSX: MYG) today announced the administration of MGCD290 as a single agent to the first cohort of healthy adult volunteers in a Phase I clinical study. MGCD290 is an orally available fungal Hos2 inhibitor designed to be used in combination with azoles for the treatment of fungal infections....

  Articles 2008-10-15

• Methylgene Receives Clinical Trial Approval from Health Canada for its Proprietary Product Candidate MGCD290 for Fungal Infections

  MethylGene Inc. (TSX: MYG) today announced that Health Canada has approved the Company's clinical trial application CTA for MGCD290, a fungal Hos2 histone deacetylase HDAC inhibitor to be used in combination with azoles for the treatment of fungal infections. MethylGene expects to initiate a Phase I clinical trial in Canada...

  Articles 2008-10-02

• BellwetherReport.com Analyst Opinions on DELL, QCOR, PTEN and OXGN

  BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...

  Articles 2008-10-01

• Genesco Declares Quarterly Dividends

  NASHVILLE, Tenn., Sept. 30 /PRNewswire-FirstCall/ -- The board of directors of Genesco Inc. has declared dividends on the various classes of its preferred stock for the quarter ending November 1, 2008, payable on October 30, 2008, to shareholders of record on October 15, 2008. The rates...

  Articles 2008-09-30

• MethylGene Exercises Right to Convert MGCD0103 Collaboration with Celgene to Pre-Determined Royalty and Milestone Arrangement

  MethylGene Inc. (TSX: MYG) today announced that it has exercised its right to convert to a royalty stream and milestone arrangement with Celgene Corporation for MGCD0103 as provided under the license and collaboration agreement between the companies formed in January 2006. By taking this action, MethylGene, after a 90-day transition...

  Articles 2008-09-19

• Genelabs Technologies, Inc. Announces Appointment of Frederick W. Driscoll as President and CEO

  REDWOOD CITY, Calif. -- Genelabs Technologies, Inc. (NASDAQ:GNLB) today announced the appointment of Frederick W. Driscoll as President and Chief Executive Officer and as a member of its Board of Directors. Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. ...

  Articles 2008-09-03

• John Kollins

  John Kollins has been promoted to chief operating officer at OXiGENE Inc. He had been senior vice president and chief business officer for the biopharmaceutical firm...

  Articles 2008-08-18